Characterization of adrenoceptor involvement in skeletal and cardiac myotoxicity induced by sympathomimetic agents: Toward a new bioassay for β-blockers

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 4, 2003, Pages 518-525

  Tan, Lip Bun ^a,d   Burniston, Jatin G ^b   Clark, William A ^c   Ng, YeeLan ^b   Goldspink, David F ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c MICHAEL REESE HOSPITAL   (United States)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Adrenergic receptors; Beta adrenergic agonists and antagonists; Cardiomyocytes; Immunohistochemistry; Necrosis

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ADRENERGIC RECEPTOR STIMULATING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUPRANOLOL; CLENBUTEROL; ISOPRENALINE; PHENOXYBENZAMINE; PRAZOSIN; PROPANOL; YOHIMBINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BETA ADRENERGIC STIMULATION; BIOASSAY; CARDIOTOXICITY; DOSE RESPONSE; DRUG DETERMINATION; DRUG SENSITIVITY; HEART FAILURE; HEART MUSCLE; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE NECROSIS; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SKELETAL MUSCLE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BIOLOGICAL ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MUSCLE, SKELETAL; MYOCYTES, CARDIAC; NECROSIS; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC; SYMPATHOMIMETICS;

EID: 0037379901     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200304000-00003     Document Type: Article

References (47)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-55.
2. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II: a randomized trial. Lancet. 1999;353:9-13.
3. MERIT-HF Study Group Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet. 1999;353:2001-7.
4. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-79.
5. Coats AJS, Anker SD, Roecker EB, et al. Prevention and reversal of cardiac cachexia in patients with severe heart failure by carvedilol: Results of the COPERNICUS Study. Circulation. 2001;II-437.
6. Post SR, Hammond HK, Insel PA. β-adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol. 1999;39:343-360.
7. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-23.
8. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526-34.
9. Macefield VG, Rundqvist B, Sverrisdottir YB, et al. Firing properties of single muscle vasoconstrictor neurons in the sympatho-excitation associated with congestive heart failure. Circulation. 1999;100:1708-13.
10. Ogita H, Shimonagata T, Fukunami M, et al. Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656-60.
11. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation. 1997;96:2953-8.
12. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J. 1999;138:95-9.
13. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985;17:291-306.
14. Benjamin IJ, Jalil JE, Tan LB, et al. Isoproterenol-induced myocardial fibrosis in relation myocyte necrosis. Circ Res. 1989;65:657-70.
15. Tan LB, Benjamin IJ, Clark WA. Beta-adrenergic receptor desensitization may serve a cardioprotective role. Cardiovasc Res. 1992;26:608-14.
16. Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats. Circ Res. 1999;75:105-13.
17. Opasich C, Ambrosino N, Felicetti G, et al. Heart failure-related myopathy: clinical and pathophysiological insights. Eur Heart J. 1999;20:1191-200.
18. Ferrari R. Origin of heart failure: cardiac or generalized myopathy? Eur Heart J. 1999;20:1613-4.
19. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51:651-89.
20. The Beta-blocker Evaluation of Survival Trial (BEST) Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-67.
21. Clark WA Jr, Everett AW, Fitch FW, et al. Characterization of monoclonal antibodies directed against determinants on cardiac myosin heavy chain. Biochem Biophys Res Commun. 1980;95:1680-6.
22. Nolan AC, Clark WA, Karwoski T, et al. Patterns of cellular injury in myocardial ischemia determined by monoclonal antimyosin. Proc Natl Acad Sci USA. 1983;80:6046-50.
23. Tan LB, Jalil JE, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-95.
24. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest. 1996;74:86-107.
25. Ng Y, Goldspink DF, Clark WA, et al. Isoprenaline induces myocyte necrosis in rat skeletal muscle: comparison with effects on cardiomyocytes. Int J Cardiol. 2002;86:299-309.
26. Klemola R, Huttunen P, et al. Catecholamines in the pericardial fluid of normotensive, spontaneously hypertensive and reserpine-treated rats. Acta Physiol Scand. 1999;165:293-7.
27. Vaishali HS, Kunjan RD, et al. Effect of catecholamine depletion on oxidative energy metabolism in the rat liver, brain and heart mitochondria; use of reserpine. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 2000;127:79-90.
28. Grimm M, Kurz T, Schwarz M, et al. Presynaptic regulation of cardiac norepinephrine release in ischemia. J Cardiovasc Pharmacol. 2001;38:58-68.
29. Rothwell NJ, Stock MJ, Sudera DK. Changes in tissue blood flow and β-receptor density of skeletal muscle in rats treated with the β-adrenoceptor agonist isoproterenol. Br J Pharmacol. 1987;90:601-607.
30. Baker AJ, Head SI, Wareham AC, et al. Effect of clenbuterol on sarcoplasmic reticulum function in single skinned mammalian skeletal fibers. Am J Physiol. 1998;274(6 part 1):C1718-26.
31. Steinberg SF. The molecular basis for distinct β-adrenergic receptor subtype actions in cardiomyocytes. Circ Res. 1999;85:1101-11.
32. Reimer KA, Jennings RB. Myocardial ischemia, hypoxia and infarction. In: Fozzard HA, ed. The heart and cardiovascular system. New York: Raven Press, 1986:1133-1201.
33. 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203-42.
34. Adams KF Jr. Which β-blocker for heart failure? Am Heart J. 2001;141:884-8.
35. Willette RN, Aiyar N, Yue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther. 1999;289:48-53.
36. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6. [Published erratum appears in Lancet. 1990;336:698.]
37. Soriano JB, Hoes AW, Meems L, et al. Increased survival with beta-blockers: Importance of ancillary properties. Prog Cardiovasc Dis. 1997;39:445-56.
38. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure differential effects on sympathetic activity. Circulation. 2001;104:2194-2199.
39. Brunner-La Rocca HP, Esler MD, Jennings GL, et al. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J. 2001;22:1136-43.
40. Engelhardt S, Hein L, Wiesmann F, et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA. 1999;96:7059-64.
41. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817-30.
42. 2-adrenergic receptor over expression in mouse hearts. Circulation. 2000;101:1707-14.
43. 2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gaq-over expressing mice. Proc Natl Acad Sci USA. 1999;96:6400-5.
44. sα mouse. J Clin Invest. 1999;104:551-8
45. Mancini DM, Henson D, LaManca J, et al. Evidence of reduced respiratory muscle endurance in patients with heart failure. J Am Coll Cardiol. 1994;24:972-81.
46. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic hear failure. Lancet. 1997;349: 1050-3.
47. Murdoch DR, McMurray, JJV. Cardiac cachexia - lean and mean. Eur Heart J 1999;20:1609-11.